Hormonal
Higher circulating levels of plasma very-long-chain saturated fatty acids (VLCSFAs: C20:0, C22:0, C24:0) are associated with a significantly lower risk of incident coronary heart disease (CHD) in US men and women.
This observational study suggests that higher levels of specific very-long-chain saturated fatty acids (C20:0, C22:0, C24:0) in the blood are linked to a lower risk of heart disease. However, this does not mean you should intentionally consume more of these fats, as their source and overall dietary context are critical. The findings highlight the complexity of lipid metabolism and suggest that blood markers of these fatty acids may serve as useful indicators of cardiovascular health rather than direct targets for supplementation.
After multivariate adjustment for lifestyle factors, body mass index, diet, and long-chain n-3 and trans fatty acids, total VLCSFAs in plasma were associated with a 52% decreased risk of CHD (pooled hazard ratio, 0.48; 95% confidence interval, 0.32–0.72, comparing extreme quintiles; Ptrend<0.0001).
Why this rating
Large prospective cohorts (NHS and HPFS) with rigorous matching and adjustment for confounders, though observational design prevents causal inference.
Source
Circulating Very-Long-Chain Saturated Fatty Acids and Incident Coronary Heart Disease in US Men and Women
Vasanti Malik et al. · Circulation · 2015
DOI 10.1161/circulationaha.114.014911
More from this paper
- Circulating very-long-chain saturated fatty acids (VLCSFAs) in plasma are associated with favorable cardiovascular risk markers, including higher HDL-C, lower triglycerides, and higher adiponectin.Good
- Circulating very-long-chain saturated fatty acids (VLCSFAs) in erythrocytes are NOT significantly associated with a reduced risk of incident coronary heart disease (CHD) after multivariate adjustment.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →